Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features

British Journal of Dermatology

Volumn 162, Issue 4, 2010, Pages 772-779

  Ghafouri Fard, S ^a   Abbasi, A ^a   Moslehi, H ^b   Faramarzi, N ^a   Taba Taba Vakili, S ^a   Mobasheri, M B ^a   Modarressi, M H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Basal cell carcinoma; Cancer immunotherapy; Cancer testis antigen; ODF; SPATA19; TEX101

Indexed keywords

CANCER TESTIS ANTIGEN; OUTER DENSE FIBER 1 PROTEIN; OUTER DENSE FIBER 2 PROTEIN; OUTER DENSE FIBER 3 PROTEIN; OUTER DENSE FIBER 4 PROTEIN; PAS DOMAIN CONTAINING 1 PROTEIN; SPERMATOGENESIS ASSOCIATED 19 PROTEIN; TESTIS EXPRESSED 101 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; HEAT SHOCK PROTEIN; MITOCHONDRIAL PROTEIN; PASD1 PROTEIN, HUMAN; SEMINAL PLASMA PROTEIN; SPATA19 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALYSIS OF VARIANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SKIN TUMOR; TESTIS; TUMOR GENE;

ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CARCINOMA, BASAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HEAT-SHOCK PROTEINS; HUMANS; MALE; MITOCHONDRIAL PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMINAL PLASMA PROTEINS; SKIN NEOPLASMS; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949844411     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09568.x     Document Type: Article

References (34)

1. Armstrong BK, Kricker A. Skin cancer. Dermatol Clin 1995 13 : 583 594.
2. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003 327 : 794 798.
3. Housman TS, Feldman SR, Williford PM et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003 48 : 425 429.
4. Tilli CM, van Steensel MA, Krekels GA et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005 152 : 1108 1124.
5. Kaporis HG, Guttman-Yassky E, Lowes MA et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007 127 : 2391 2398.
6. Kalejs M, Erenpreis J. Cancer/testis antigens and gametogenesis: a review and 'brain-storming' session. Cancer Cell Int 2005 5 : 4 15.
7. Zendman AJW, Ruiter DJ, van Muijen GNP. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003 194 : 272 288.
8. Costa FF, Blanc KL, Brodin B. Concise review: cancer/testis antigens, stem cells and cancer. Stem Cells 2007 25 : 707 711.
9. Dym M, Fawcett DW. The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. Biol Reprod 1970 3 : 308 326.
10. Fawcett DW, Leak LV, Heidger PM Jr. Electron microscopic observations on the structural components of the blood-testis barrier. J Reprod Fertil Suppl 1970 10 : 105 122.
11. Pelletier RM, Byers SW. The blood-testis barrier and Sertoli cell junctions: structural considerations. Microsc Res Tech 1992 20 : 3 33.
12. Dave DS, Leppert JT, Rajfer J. Is the testis a chemo-privileged site? Is there a blood-testis barrier? Rev Urol 2007 9 : 28 32.
13. Fiszer D, Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol 1998 40 : 172 176.
14. Simpson AJ, Caballero OL, Jungbluth A et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005 5 : 615 625.
15. Mobasheri MB, Modarressi MH, Shabani M et al. Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). Leuk Res 2006 30 : 883 889.
16. Mobasheri MB, Jahanzad I, Mohagheghi MA et al. Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev 2007 31 : 296 302.
17. Theinert SM, Pronest MM, Peris K et al. Identification of the testis-specific protein 10 (TSGA10) as serologically defined tumour-associated antigen in primary cutaneous T-cell lymphoma. Br J Dermatol 2005 153 : 639 641.
18. Gniadecki R, Wulf HC. Epidermal stem cells - role in normal, wounded and pathological psoriatic and cancer skin. Curr Stem Cell Res Ther 2008 3 : 146 150.
19. Kamstrup MR, Gniadecki R, Skovgaard GL. Putative cancer stem cells in cutaneous malignancies. Exp Dermatol 2007 16 : 297 301.
20. Takayama T, Mishima T, Mori M et al. TEX101 is shed from the surface of sperm located in the caput epididymidis of the mouse. Zygote 2005 13 : 325 333.
21. Kierszenbaum AL. Keratins: unraveling the coordinated construction of scaffolds in spermatogenic cells. Mol Reprod Dev 2002 61 : 1 2.
22. Lindemann CB. Functional significance of the outer dense fibers of mammalian sperm examined by computer simulations with the geometric clutch model. Cell Motil Cytoskeleton 1996 34 : 258 270.
23. Suzuki-Toyota F, Ito C, Toyama Y et al. Factors maintaining normal sperm tail structure during epididymal maturation studied in Gopc-/- mice. Biol Reprod 2007 77 : 71 82.
24. Liggins AP, Brown PJ, Asker K et al. A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 2004 91 : 141 149.
25. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003 62 : 593 604.
26. Tomas S. Difficult to diagnose skin cancer - the 'aggressive' BCC. Aust Fam Physician 2009 38 : 492 497.
27. Dadabayev AR, Wang Z, Zhang Y et al. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? Am J Hematol 2005 80 : 6 11.
28. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002 94 : 477 485.
29. Stevenson BJ, Iseli C, Panji S et al. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007 8 : 129 139.
30. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 2009 12 : 395 404.
31. Chiriva-Internati M, Wang Z, Salati E. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand J Immunol 2002 56 : 429 433.
32. Nicholaou T, Ebert LM, Davis ID et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009 15 : 2166 2173.
33. Hirohashi Y, Torigoe T, Inoda S et al. The functioning antigens: beyond just as the immunological targets. Cancer Sci 2009 100 : 798 806.
34. Hassanpour SE, Kalantar-Hormozi A, Motamed S et al. Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg 2006 57 : 509 512.